TL1A as a therapeutic target in inflammatory bowel disease

Expert Rev Clin Immunol. 2022 Jun;18(6):551-555. doi: 10.1080/1744666X.2022.2074401. Epub 2022 May 12.

Authors

Georgios Kokkotis¹, Giorgos Bamias¹

Affiliation

¹ GI Unit, 3 Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, Athens, Greece.

PMID: 35507314
DOI: 10.1080/1744666X.2022.2074401

No abstract available

Keywords: IBD; TL1A; TNFSF15; intervention; mucosal immunity.

Publication types

Editorial

MeSH terms

Humans
Inflammatory Bowel Diseases* / therapy
Tumor Necrosis Factor Ligand Superfamily Member 15

Substances

Tumor Necrosis Factor Ligand Superfamily Member 15